





VENABLE | Fitzpatrick


October 31, 2019











FWD = Final Written Decision



Spotlight On: Adalimumab

VENABLE | Fitzpatrick

October 31, 2019

Technology: Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha (TNF α). TNF α is a cytokine cell signaling protein that is involved in the inflammatory response that occurs in autoimmune diseases.

	AbbVie v. Amgen 1:16-cv-00666 (D. Del.) Settled	AbbVie v. Boehringer Ingelheim 1:17-cv-01065 (D. Del.) Settled	Amgen v. AbbVie IPR2015-01514 Institution denied	Amgen v. AbbVie IPR2015-01517 Institution denied
8,663,945	x			
8,911,964	x			
8,916,157	x		x	
8,916,158				x
8,926,975		X		
8,961,973	x			
8,986,693	X			
9,018,361		X		
9,090,867		х		
9,096,666	х	х		
9,220,781	Х			
9,255,143		х		
9,266,949		х		
9,272,041	Х	х		
9,359,434	X			
9,365,645	Х			
9,546,212		х		
	Coherus v. AbbVie IPR2016-00172 FWD: All claims unpatentable; Appeal No. 17-2304 pending with U.S. as Intervenor (Coherus settled)	Boehringer Ingelheim v. AbbVie IPR2016-00408, IPR2016-00409 FWD: All claims unpatentable; Appeal Nos. 17-2362 and 17- 2363 pending with U.S. as Intervenor (Boehringer Ingelheim settled)	Coherus v. AbbVie IPR2016-00188 FWD: All claims unpatentable; Appeal No. 17-2305 pending with U.S. as Intervenor (Coherus settled)	Coherus v. AbbVie IPR2016-00189 FWD: All claims unpatentable; Appeal No. 17-2306 pending with U.S. as Intervenor (Coherus settled)
8,889,135	x	x		
9,017,680			x	
9,073,987				x

	Coherus v. AbbVie IPR2017-00822, IPR2017-00823 Institution denied	Coherus v. AbbVie IPR2017-00826 / IPR2017- 01008 Institution denied		Coherus v. AbbVie IPR2017-00827 / IPR2017- 01009 Institution denied
9,085,619	x	x		x
	<i>Sandoz v. AbbVi</i> e IPR2017-01823 Institution denied	Sandoz v. AbbVie IPR2017-01987 Institution denied; Settled during request for rehearing		Sandoz v. AbbVie IPR2017-01988 Institution denied; Settled during request for rehearing
8,802,100	x			
8,911,737		X		
8,974,790				X
	Sandoz v. AbbVie IPR2017-02106 Settled after institution	Sandoz v. AbbVie IPR2017-02105 Settled after institution		Coherus v. AbbVie IPR2016-01018 Institution denied
9,067,992	х			
9,090,689		х		
9,114,166				х
	Sandoz v. AbbVie IPR2017-01824 Institution denied; Request for rehearing denied; Appeal No. 18-2142 settled Ap		Sandoz v. AbbVie IPR2018-00002 Institution denied; peal No. 18-2143 settled	
9,512,216	х			х
	Sandoz v. AbbVie IPR2018-00156 Institution denied	AbbVie v. Sandoz 3:18-cv-12668 (D.N.J.) Settled		Coherus v. Amgen [Related to Amjevita™] 1:19-cv-00139 (D. Del.) Ongoing
9,187,559	х	х		
9,750,808		х		
10,155,039				Х
10,159,732				Х
10,159,733				Х
10,207,000				x